Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma

Although recent advances have substantially improved the management of multiple myeloma, it remains an incurable malignancy. We now demonstrate that anti-CD138 molecules genetically fused to type I interferons (IFN) synergize with the approved therapeutic bortezomib in arresting the proliferation of...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:MAbs
Huvudupphovsmän: Vasuthasawat, Alex, Yoo, Esther M., Trinh, Kham R., Lichtenstein, Alan, Timmerman, John M., Morrison, Sherie L.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Taylor & Francis 2016
Ämnen:
Report
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5058616/
https://ncbi.nlm.nih.gov/pubmed/27362935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2016.1207030
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk